Cevian Capital II G.P. Limited increased its aggregate voting rights in Smith & Nephew plc to 14.214414% as of August 7, 2026. This represents an increase from the previously notified holding of 14.010786%, driven by rises in both the Cevian Capital II Master Fund L.P. (to 13.014856%) and the Cevian Capital II Co-Investment - Series P L.P. (to 1.199558%). The filing does not indicate that a new notification threshold was crossed. Smith & Nephew plc operates in the medical technology industry, manufacturing orthopaedic, sports medicine, and wound management products.
